Clinical trials: Advanced Tumor
Solid Tumors (Phase 1)
A Early Study of ABSK131 in Patients With Advanced/Metastatic Solid Tumors
This is a first-in-human (FIH), multicenter, non-randomized, openlabel, phase 1 study of ABSK131 in patients with MTAP-Deficient Advanced/Metastatic Solid Tumors to evaluate the safety, tolerability, PK, and preliminary antitumor…
- Trial name
- ABSK131-101 (NCT07288957)
- Testing
- ABSK131
- Where
- China
- Volunteers
- 266 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Carcinoma, Hepatocellular
Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)
This is a multi-centre, phase II study to assess the efficacy and safety of ZD6474 in patients with Child-Pugh class A, inoperable HCC. This study comprises 2 phases, the primary treatment phase and the secondary treatment phase.
- Trial name
- NCT00508001
- Testing
- Vandetanib, Best Supportive Care
- Where
- 3 sites in Taiwan
- Volunteers
- 67 people
- Sponsor
- Genzyme, a Sanofi Company
Solid Cancers
A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
This is a two stage, Phase Ib study designed to describe the pharmacokinetics of GDC-0449 in patients with advanced solid tumors that are refractory to treatment or for whom no standard therapy exists.
- Trial name
- NCT00968981
- Testing
- GDC-0449
- Volunteers
- 67 people
- Sponsor
- Genentech, Inc.
Breast Neoplasms
Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms
To evaluate the preliminary activity and pharmacokinetics of 2 separate doses and schedules of orally administered Temsirolimus (CCI-779) given in combination with daily letrozole, compared to letrozole alone, in the treatment of…
- Trial name
- NCT00062751
- Testing
- Letrozole / Temsirolimus (CCI-779), Letrozole
- Volunteers
- 108 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy.
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone, Lymphoma, Non-Hodgkin, Multiple Myeloma
- Trial name
- NCT05024045
- Testing
- LOXO-338, Pirtobrutinib
- Where
- 23 sites in United States, France and 2 more
- Volunteers
- 27 people
- Sponsor
- Eli Lilly and Company
Stomach Neoplasms, Esophageal Neoplasms
Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to assess objective tumor response in the single agent treatment of PEP02, irinotecan, or docetaxel for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
- Trial name
- NCT00813072
- Testing
- PEP02, irinotecan, docetaxel
- Where
- 22 sites in Bosnia and Herzegovina, Croatia and 4 more
- Volunteers
- 135 people
- Sponsor
- PharmaEngine
Melanoma
Study of PI-88 in Patients With Advanced Melanoma
The purpose of this study is to determine whether PI-88 is safe and effective in the treatment of advanced melanoma.
- Trial name
- NCT00068172
- Testing
- PI-88
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Cellxpert Biotechnology Corp.
Ovarian Cancer
Determine MTD, Evaluate Efficacy and Safety of Genexol®-PM Plus Carboplatin With Advanced Ovarian Cancer
The purpose of this study is to determine the maximum tolerated dose of Genexol®-PM plus Carboplatin and evaluate the efficacy and safety of Genexol®-PM plus Carboplatin regimen in subjects with advanced ovarian cancer.
- Trial name
- NCT00877253
- Testing
- Genexol-PM 220mg/㎡, Carboplatin 5AUC, Genexol-PM 260mg/㎡, Carboplatin 5AUC, Genexol-PM 300mg/㎡, Carboplatin 5AUC
- Volunteers
- 18 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Non-small Cell Lung Cancer (NSCLC)
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without…
- Trial name
- TROPION-Lung17 (NCT07291037)
- Testing
- Datopotamab deruxtecan (Dato-DXd), Docetaxel
- Where
- 206 sites in United States, Australia and 19 more
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Genital Neoplasms, Female
Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies
The primary objectives of this trial were to determine the safety, tolerability, and MTD of BIBF 1120 when added to standard therapy with carboplatin and paclitaxel
- Trial name
- NCT02182245
- Testing
- BIBF 1120, Paclitaxel, Carboplatin
- Volunteers
- 22 people
- Sponsor
- Boehringer Ingelheim
Hepatocellular Carcinoma, Pancreatic Cancer
A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours
This study is a trial of dexanabinol in patients with advanced tumours. The purposes of the protocol are to study different doses of the study drug to determine the maximum safe dose of the drug given in combination with standard…
- Trial name
- NCT02423239
- Testing
- Dexanabinol, Sorafenib, Nab-paclitaxel
- Where
- 13 sites in Germany, Poland and 2 more
- Volunteers
- 112 people
- Sponsor
- e-Therapeutics PLC
Non Small Cell Lung Cancer
Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients
This 2 step study aims to establish a tolerable dose level and regimen of RAD001 in patients with advanced NCLC not previously treated with systemic therapy.
- Trial name
- NCT00457119
- Testing
- RAD001
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 69 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Study of SM-88 in Advanced Cancers
The purpose of this study is to collect response and pharmacokinetic data on the oral administration of a cocktail combination of 4 drugs being developed for the indication of metastatic breast cancer.
- Trial name
- NCT02562612
- Testing
- SM-88
- Volunteers
- healthy volunteers welcome
- Sponsor
- Tyme, Inc
Solid Tumors
Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.
- Trial name
- NCT06963281
- Testing
- IBI3020
- Where
- 9 sites in United States, China
- Volunteers
- 285 people
- Sponsor
- Fortvita Biologics (USA)Inc.
Non-Squamous Non-Small Cell Lung Cancer
A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.
This study will assess the prevalence of epidermal growth factor receptor (EGFR) mutations in newly diagnosed patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Trial name
- NCT01250119
- Testing
- erlotinib [Tarceva]
- Where
- 22 sites in United Kingdom
- Volunteers
- 688 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumor
A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)
This is an open-label, multicenter, Phase 1/2, first-in-human (FIH), dose-escalation and cohort-expansion study of LAT010 to evaluate the safety, tolerability, immunogenicity, PK, PD, and antitumor activity in patients with…
- Trial name
- LIGHTSPEED-1 (NCT06277219)
- Testing
- LAT010, LAT010 + ICI
- Where
- 4 sites in United States, China
- Volunteers
- 150 people
- Sponsor
- Latticon Antibody Therapeutics, Inc
Neoplasms
BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours
This Phase I study will investigate the safety of BIBW 2992 in combination with standard dose pemetrexed (500mg/m2) given on a 21 day cycle in patients with advanced solid cancers.
- Trial name
- NCT01169675
- Testing
- BIBW 2992 low dose, BIBW 2992 high dose, pemetrexed
- Where
- 2 sites in Canada
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim
Primary Peritoneal Carcinoma, Tumor
Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors
This is an open-label, two-arm, multicenter feasibility study to evaluate the safety and tolerability of pazopanib in combination with carboplatin and paclitaxel in female subjects with newly diagnosed advanced gynaecological…
- Conditions
- Primary Peritoneal Carcinoma, Tumor, Epithelial Ovarian Cancer, Uterine Disease
- Trial name
- NCT00561795
- Testing
- pazopanib (GW786034), carboplatin, paclitaxel
- Where
- 5 sites in France, Germany
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumors
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced solid tumors.
- Trial name
- NCT06795412
- Testing
- PYX-201, pembrolizumab
- Where
- 22 sites in United States, France and 1 more
- Volunteers
- 220 people
- Sponsor
- Pyxis Oncology, Inc
Breast Cancer
TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.
This is a retrospective, observational study that will document the treatment and monitoring patterns and clinical outcomes of patients diagnosed with HR+/HER2- a/mBC who received Palbociclib combination therapy with aromatase…
- Trial name
- NCT04498481
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.